

**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**



## TABLE OF CONTENTS

GENERIC DRUG NAME	PAGE
Adenosine .....	3
Albuterol .....	4
Amiodarone .....	5
Aspirin .....	6
Atropine: Bradycardia .....	7
Atropine: Nerve Agent/Organophosphate Poisoning .....	8
Calcium Chloride 10% .....	9
Dextrose .....	10
Diphenhydramine .....	11
Epinephrine: Cardiac Arrest .....	12
Epinephrine: Neonatal Resuscitation .....	13
Epinephrine: Pediatric Bradycardia .....	14
Epinephrine: Severe Respiratory Distress .....	15
Epinephrine: Allergic Reaction/Anaphylaxis .....	16
Fentanyl .....	17
Glucagon .....	18
Glucose Gel .....	19
Hydroxocobalamin .....	20-21
Ipratropium .....	22
Midazolam .....	23
Naloxone .....	24
Nitroglycerin .....	25
Ondansetron .....	26
Oxygen .....	27
Pralidoxime .....	28
Sodium Bicarbonate 8.4% .....	29



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Adenosine
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Adenosine</b>
<b>DRUG NAME - TRADE</b>	Adenocard
<b>DRUG CLASSIFICATION</b>	Antiarrhythmic
<b>DOSAGE FORMS</b>	6 mg/2 mL, Injection, Prefilled syringe or vial
<b>ACTION(S)</b>	Slows conduction through AV node and interrupts AV reentry pathways to restore normal sinus rhythm
<b>INDICATIONS</b>	For Stable Patients: Treatment of regular, narrow complex supraventricular tachycardia (SVT)
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• Known or documented hypersensitivity</li> <li>• Sick sinus syndrome</li> <li>• 2nd or 3rd degree AV block</li> <li>• Poison or drug-induced tachycardia</li> <li>• Atrial fibrillation/flutter</li> <li>• Ventricular tachycardia</li> <li>• Wolff-Parkinson-White (WPW) syndrome</li> <li>• Use with caution in asthma and COPD</li> </ul>
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Antecubital IV access</li> <li>• Initial dose: 6 mg rapid IV (over 1-2 seconds) followed immediately by 10 mL rapid saline flush and extremity elevation</li> <li>• If first dose does not terminate dysrhythmia in 1-2 minutes, give 12 mg rapid IV followed by 10 mL rapid saline flush and extremity elevation</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Antecubital IV access, if possible</li> <li>• Initial dose of 0.1 mg/kg rapid IV/IO over 1-2 seconds followed immediately by 2- 5 mL rapid saline flush and extremity elevation</li> <li>• Max initial dose 6 mg</li> <li>• If first dose does not terminate SVT in 1-2 minutes, give 0.2 mg/kg rapid IV/IO followed immediately by 2- 5 mL rapid saline flush and extremity elevation. Max repeat dose 12 mg</li> </ul>
<b>SIDE EFFECTS</b>	<ul style="list-style-type: none"> <li>• Common reactions are generally mild and short-lived: sense of impending doom, flushing, chest pressure, throat tightness, numbness</li> <li>• Patients may have a brief episode of one or more transient dysrhythmias, which may include asystole</li> <li>• Adenosine is a respiratory stimulant; can exacerbate asthma and COPD</li> </ul>



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Albuterol
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Albuterol</b>
<b>DRUG NAME - TRADE</b>	Proventil, Ventolin, Proair
<b>DRUG CLASSIFICATION</b>	Bronchodilator, beta agonist
<b>DOSAGE FORMS</b>	0.083%, 2.5 mg/3 mL, inhalation, vial
<b>ACTION(S)</b>	Bronchial smooth muscle relaxation via beta-2 receptors.
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Asthma</li> <li>• Bronchitis with bronchospasm</li> <li>• COPD with wheezing</li> <li>• Allergic reaction/anaphylaxis with wheezing</li> </ul>
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• Known or documented hypersensitivity</li> <li>• Use with caution in patients with cardiovascular disease history, tachycardia secondary to cardiac condition, croup</li> </ul>
<b>ADULT DOSE / ROUTE</b>	2.5 mg of 0.083% (3 mL) via nebulizer (6 LPM oxygen) until mist stops, usually 5-15 minutes.
<b>PEDIATRIC DOSE / ROUTE</b>	
<b>SIDE EFFECTS</b>	<ul style="list-style-type: none"> <li>• Common side effects include palpitations, tachydysrhythmia, anxiety, tremors, nausea/vomiting</li> <li>• Rarely, paradoxical bronchospasm can occur</li> </ul>





**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Amiodarone
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Amiodarone</b>
<b>DRUG NAME - TRADE</b>	Pacerone, Cordarone
<b>DRUG CLASSIFICATION</b>	Antiarrhythmic
<b>DOSAGE FORMS</b>	150 mg/3ml, Injection, Vial
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Class III antiarrhythmic which inhibits adrenergic stimulation</li> <li>• Affects sodium, potassium, and calcium channels</li> <li>• Increases the cardiac refractory period and prolongs action potential and repolarization in myocardium</li> <li>• Decreases AV conduction and sinus node function</li> </ul>
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Cardiac arrest with shock refractory ventricular fibrillation (V-Fib) or pulseless ventricular tachycardia (V-Tach)</li> </ul>
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• No Contraindications in pulseless cardiac arrest</li> <li>• Do not administer to patients with return of spontaneous circulation/pulse</li> </ul>
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• 300 mg IV/IO bolus after 3<sup>rd</sup> defibrillation. Repeat dose of 150 mg IV/IO bolus after 5<sup>th</sup> defibrillation if patient remains in pulseless shockable rhythm</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Ventricular Fibrillation/Pulseless Ventricular Tachycardia: Amiodarone 5 mg/kg IV/IO. May Repeat x2.</li> <li>• Max dose 300mg</li> </ul>
<b>SIDE EFFECTS</b>	<ul style="list-style-type: none"> <li>• Common side effects include hypotension, bradycardia, AV block, dysrhythmias, nausea, vomiting</li> <li>• QT prolongation</li> </ul>



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Aspirin
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Aspirin</b>
<b>DRUG NAME - TRADE</b>	Ecotrin, Bayer
<b>DRUG CLASSIFICATION</b>	Antiplatelet agent
<b>DOSAGE FORMS</b>	81 mg, chewable, bottle
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Inhibits synthesis of prostaglandin by cyclooxygenase</li> <li>• Inhibits platelet aggregation</li> <li>• Has antipyretic and analgesic activity</li> </ul>
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Suspected acute coronary syndrome (ACS) or chest pain suspicious for cardiac origin</li> </ul>
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• Known or documented hypersensitivity to aspirin or NSAIDS</li> <li>• Bleeding diathesis, hemophilia, GI Bleeding/active ulcers, hemorrhagic stroke, history of bleeding or clotting disorders</li> </ul>
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• 324 mg (4 x 81 mg chewable tablets), chewed and swallowed</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	N/A
<b>SIDE EFFECTS</b>	<ul style="list-style-type: none"> <li>• Possible side effects include bleeding, stomach irritation, nausea and vomiting</li> </ul>



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Atropine - Symptomatic Bradycardia

Approved: EMS Medical Directors Consortium

Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Atropine: Symptomatic Bradycardia</b>
<b>DRUG NAME - TRADE</b>	Atropine
<b>DRUG CLASSIFICATION</b>	Anticholinergic
<b>DOSAGE FORMS</b>	1 mg/10 mL, Injection, Prefilled syringe
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Reverses cholinergic-mediated decreases in heart rate</li> <li>• Increases SA and AV node conduction</li> </ul>
<b>INDICATIONS</b>	Symptomatic bradycardia
<b>CONTRAINDICATIONS</b>	No absolute contraindications for ACLS
<b>ADULT DOSE / ROUTE</b>	Bradycardia: 0.5 mg rapid IV q 3-5 minutes up to 3 mg total
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Bradycardia: 0.02 mg/kg rapid IV/IO</li> <li>• Max single dose 0.5 mg. May repeat once.</li> </ul>
<b>SIDE EFFECTS</b>	Decreased secretions/dry mouth, intense facial flushing and hot skin temperature, blurred vision or pupil dilation, photophobia, tachycardia, restlessness



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Atropine – Nerve Agent & Organophosphate Poisoning
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Atropine: Nerve Agent and Organophosphate Poisoning</b>
<b>DRUG NAME - TRADE</b>	Atropine, AtroPen, component of Mark 1 Kits and DuoDote
<b>DRUG CLASSIFICATION</b>	Anticholinergic, antidote for organophosphate and nerve agent poisoning
<b>DOSAGE FORMS</b>	<ul style="list-style-type: none"> <li>• Chempak atropine: 0.4mg/ml (20 mg vial)</li> <li>• Duodote: 2 mg atropine</li> <li>• Mark 1 Kit: 2 mg atropine</li> </ul>
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Competitively inhibits action of acetylcholine at muscarinic receptor sites. Receptors affected include salivary, bronchial, sweat glands, eyes, heart and GI tract (most-to-least sensitive)</li> <li>• Increases SA and AV node conduction</li> <li>• Dries secretions</li> </ul>
<b>INDICATIONS</b>	For the management of toxicity caused by organophosphate insecticides and nerve agents poisoning (e.g. tabun, sarin, soman) including muscle fasciculations, nausea and vomiting, copious secretions, bradycardia, weakness, shortness of breath, unconsciousness, convulsions, paralysis and apnea
<b>CONTRAINDICATIONS</b>	Known or documented hypersensitivity in non-ACLS/nerve agent/organophosphate scenarios
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Nerve Agent/Organophosphate Poisoning: 2 mg IM and titrate until desired effect (drying of tracheobronchial secretions, improvement of breathing and bradycardia)</li> <li>• No max dose.</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Pediatric nerve agent/organophosphate exposure dosages are not included in the Drug Appendix</li> <li>• See Protocol: HAZ MAT / NERVE AGENTS - PEDIATRIC - ALS</li> </ul>
<b>SIDE EFFECTS</b>	Decreased secretions/dry mouth, intense facial flushing and hot skin temperature, blurred vision or pupil dilation, photophobia, tachycardia, restlessness



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Calcium Chloride 10%
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Calcium Chloride 10%</b>
<b>DRUG NAME - TRADE</b>	NONE
<b>DRUG CLASSIFICATION</b>	Calcium Salt, Electrolyte replacement
<b>DOSAGE FORMS</b>	10%, 1 gram/10 mL, Injection, Prefilled syringe
<b>ACTION(S)</b>	Stabilize cardiac cell membrane in patients with hyperkalemia who are unstable or in cardiac arrest
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Suspected hyperkalemia with cardiac arrest or dysrhythmia</li> <li>• Renal patients with QRS&gt;0.12 seconds</li> <li>• Crush injuries with victim still entrapped when QRS widens, peaked T waves, or ectopy</li> </ul>
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• Known or documented hypersensitivity</li> <li>• Known or suspected digoxin toxicity</li> <li>• NOTE: Ensure proper IV function. IV extravasation is toxic to soft tissues.</li> </ul>
<b>ADULT DOSE / ROUTE</b>	Calcium Chloride 10% 1 gram/10mL injection of prefilled syringe IV/IO
<b>PEDIATRIC DOSE / ROUTE</b>	20 mg/kg IV/IO slow push (0.2 mL/kg of 10% solution. Max single dose 10 ml)
<b>SIDE EFFECTS</b>	Minimal when used as indicated.



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Dextrose
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Dextrose</b>
<b>DRUG NAME - TRADE</b>	D10, Glucose
<b>DRUG CLASSIFICATION</b>	Glucose elevating agent
<b>DOSAGE FORMS</b>	Dextrose 10% (D10), 25 grams/250 ml water OR 50 grams/500 mL water, injection
<b>ACTION(S)</b>	Increase in blood glucose concentrations
<b>INDICATIONS</b>	Hypoglycemia
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• Known or documented hypersensitivity to dextrose, corn or corn products</li> <li>• Hyperglycemia</li> </ul>
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Dextrose 10% (D10) 100 mL IV boluses until mental status improves or BS &gt; 60mg/dL</li> <li>• Note: 250 mL of D10 = 25 g glucose</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• All Ages: Dextrose 10% (D10) 5 mL/kg (0.5 g/kg) slow IV/IO using buretrol. Repeat slow IV as indicated</li> <li>• Max 250 ml (25g)</li> <li>• Newly born/Neonate: 15mL of Dextrose 10% (D10) slow IV/IO using buretrol. Repeat as indicated.</li> </ul>
<b>SIDE EFFECTS</b>	Hyperglycemia, warmth/burning from IV injection, diuresis, thrombophlebitis, tissue necrosis if IV/IO infiltrates



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Diphenhydramine
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Diphenhydramine</b>
<b>DRUG NAME - TRADE</b>	Benadryl
<b>DRUG CLASSIFICATION</b>	Antihistamine
<b>DOSAGE FORMS</b>	50 mg/1 mL, injection, vial
<b>ACTION(S)</b>	Binds and blocks histamine-1 receptors on skin, lungs, blood vessels, and GI smooth muscle
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Allergic reactions and anaphylaxis</li> <li>• Urticaria and itching related to allergic reactions</li> </ul>
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• Known or documented hypersensitivity</li> <li>• Caution in presence of CNS depressants like alcohol and drugs</li> </ul>
<b>ADULT DOSE / ROUTE</b>	50 mg IM or slow IV
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• 1 mg/kg IM or slow IV/IO</li> <li>• Max dose 50 mg</li> </ul>
<b>SIDE EFFECTS</b>	Drowsiness/sedation, dizziness, excitable state (paradoxical reaction in some children), wheezing/thickening of bronchial secretions, dry mouth



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Epinephrine – Allergic Reaction and/or Anaphylaxis

Approved: EMS Medical Directors Consortium

Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Epinephrine: Allergic Reaction and/or Anaphylaxis</b>
<b>DRUG NAME - TRADE</b>	Epinephrine, Adrenalin, EpiPen, EpiPen Jr
<b>DRUG CLASSIFICATION</b>	Adrenergic agonist
<b>DOSAGE FORMS</b>	<ul style="list-style-type: none"> <li>• 1:1,000 (1 mg/mL), injection, vial</li> <li>• 1:10,000 (0.1 mg/mL), injection, prefilled syringe</li> </ul>
<b>ACTION(S)</b>	Stimulates alpha and beta receptors resulting in increased blood pressure, increased heart rate, bronchodilation
<b>INDICATIONS</b>	Allergic reaction and/or anaphylaxis
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• None in anaphylaxis</li> <li>• Use with caution if patient has history of hypertension, angina, cardiac disease or hyperthyroidism</li> </ul>
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• <b>ALS and BLS</b> - 0.3 mg IM (0.3 mL of 1 mg/mL concentration [1:1,000]) May repeat x1 in 5-10 min.</li> <li>• <b>ALS Only</b> - Sustained severity or deterioration: 0.1 mg IV (1 ml of 0.1mg/mL concentration [1:10,000]). May repeat every 5 minutes as indicated.</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• <b>ALS</b> - 0.01 mg/kg IM (0.01 mL/kg of 1mg/mL concentration [1:1,000]). May repeat x1 in 5-10 min. Sustained severity or deterioration: 0.01 mg/kg IV/IO (0.1 mL/kg of 0.1 mg/mL concentration [1:10,000]). May repeat every 5 minutes as indicated.</li> <li>• <b>BLS</b> - If length &lt; 48 inches, 0.15mg IM (0.15 mL of 1mg/mL concentration [1:1,000]) If length ≥ 48 inches, 0.3 mg IM (0.3 mL of 1mg/mL concentration [1:1,000]) If second dose indicated, contact OLMC</li> </ul>
<b>SIDE EFFECTS</b>	Palpitations, tachycardia, hypertension, angina, anxiety, tremors, headache





**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Epinephrine – Cardiac Arrest

Approved: EMS Medical Directors Consortium

Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Epinephrine: Cardiac Arrest</b>
<b>DRUG NAME - TRADE</b>	Epinephrine
<b>DRUG CLASSIFICATION</b>	Adrenergic agonist
<b>DOSAGE FORMS</b>	1:10,000 (0.1 mg/mL), Injection, Prefilled syringe
<b>ACTION(S)</b>	Stimulates alpha and beta receptors increasing coronary and cerebral perfusion pressure during CPR
<b>INDICATIONS</b>	Cardiac arrest
<b>CONTRAINDICATIONS</b>	None in cardiac arrest.
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• 1 mg (10 mL of the 0.1mg/mL concentration [1:10,000]) IV/IO</li> <li>• Repeat q 3-5min while pulseless</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• .01 mg/kg (0.1 mL/kg of the 0.1mg/mL concentration [1:10,000]) IV/IO</li> <li>• Repeat q 3-5 min while pulseless</li> </ul>
<b>SIDE EFFECTS</b>	None in cardiac arrest



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Epinephrine: Neonatal Resuscitation

Approved: EMS Medical Directors Consortium

Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Epinephrine: Neonatal Resuscitation</b>
<b>DRUG NAME - TRADE</b>	Epinephrine
<b>DRUG CLASSIFICATION</b>	Adrenergic agonist
<b>DOSAGE FORMS</b>	1:10,000 (0.1 mg/mL), Injection, Prefilled syringe
<b>ACTION(S)</b>	Stimulates alpha and beta receptors increasing coronary and cerebral perfusion pressure
<b>INDICATIONS</b>	Neonatal/newborn bradycardia/cardiac arrest
<b>CONTRAINDICATIONS</b>	None in cardiac arrest
<b>ADULT DOSE / ROUTE</b>	N/A
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• 0.3 mL IV/IO of the 0.1mg/mL concentration (1:10,000)</li> <li>• Repeat q 3-5 minutes while pulseless</li> </ul>
<b>SIDE EFFECTS</b>	None in cardiac arrest



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Epinephrine – Pediatric Bradycardia
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Epinephrine: Pediatric Bradycardia</b>
<b>DRUG NAME - TRADE</b>	Epinephrine
<b>DRUG CLASSIFICATION</b>	Adrenergic agonist
<b>DOSAGE FORMS</b>	1:10,000 (0.1 mg/mL), Injection, Prefilled syringe
<b>ACTION(S)</b>	Stimulates alpha and beta receptors increasing heart rate and blood pressure
<b>INDICATIONS</b>	Pediatric: Bradycardia pulse <60 AND severe cardiorespiratory compromise
<b>CONTRAINDICATIONS</b>	None
<b>ADULT DOSE / ROUTE</b>	N/A
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• 0.01 mg/kg (0.1 mL/kg of the 0.1mg/mL concentration [1:10,000]) IV/IO</li> <li>• Repeat q 3-5 min during bradycardia/cardiorepiratory compromise</li> </ul>
<b>SIDE EFFECTS</b>	Palpitations, tachycardia, hypertension, angina, anxiety, tremors, headache



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Epinephrine – Severe Respiratory Distress
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Epinephrine: Severe Respiratory Distress</b>
<b>DRUG NAME - TRADE</b>	Epinephrine, Adrenalin
<b>DRUG CLASSIFICATION</b>	Adrenergic agonist
<b>DOSAGE FORMS</b>	1:1,000 (1 mg/mL), injection, vial
<b>ACTION(S)</b>	Stimulates alpha and beta receptors resulting in bronchodilation
<b>INDICATIONS</b>	Rescue therapy for severe respiratory distress from bronchospasm associated with asthma, COPD
<b>CONTRAINDICATIONS</b>	Use with caution if patient has history of hypertension, angina, cardiac disease or hyperthyroidism
<b>ADULT DOSE / ROUTE</b>	0.3 mg IM (0.3 mL of 1 mg/mL concentration [1:1,000])
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• 0.01 mg/kg IM (0.01 mL/kg of 1 mg/mL concentration [1:1,000])</li> <li>• Maximum 0.3 mg per single dose</li> </ul>
<b>SIDE EFFECTS</b>	Palpitations, tachycardia, hypertension, angina, anxiety, tremors, headache



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Fentanyl
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Fentanyl</b>
<b>DRUG NAME - TRADE</b>	Sublimaze
<b>DRUG CLASSIFICATION</b>	Opioid analgesic
<b>DOSAGE FORMS</b>	100 mcg/2 mL, injection, vial
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Opioid agonist</li> <li>• Potent narcotic analgesic with rapid onset and short duration (30-60 minutes)</li> </ul>
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Pain related to acute coronary syndrome unresponsive to nitroglycerin.</li> <li>• Pain related to burns.</li> <li>• Pain related to trauma.</li> <li>• Pain related to cardioversion or pacing</li> <li>• Severe pain as per Pain Management protocol</li> </ul>
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• Known or documented allergy to fentanyl or other opioid analgesics</li> <li>• Pregnancy with active labor</li> <li>• Dental pain</li> <li>• Chronic pain patients who are not part of hospice or palliative care</li> <li>• Hypoventilation or respiratory depression</li> <li>• Pediatrics less than 1 year of age</li> <li>• USE WITH CAUTION in the following patients: GCS&lt;15, hypotension, hypoxia</li> </ul>
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• 1 mcg/kg IV or IM/IO/IN.</li> <li>• ≤ 65 years of age – Max dose 100 mcg</li> <li>• &gt; 65 years of age – Max dose 50 mcg</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Must be &gt; 1 year old</li> <li>• 1 mcg/kg IV or IM/IO/IN, not to exceed adult max dose. No repeat dose.</li> </ul>
<b>SIDE EFFECTS</b>	<ul style="list-style-type: none"> <li>• Respiratory depression, hypotension, bradycardia, muscle rigidity, delirium, dizziness, headache, nausea, vomiting</li> <li>• Rapid infusion may cause chest wall rigidity</li> </ul>



<b>REGION 11 CHICAGO EMS SYSTEM DRUG TABLE</b>	Drug Name: Glucagon
	Approved: EMS Medical Directors Consortium

<b>DRUG NAME - GENERIC</b>	<b>Glucagon</b>
<b>DRUG NAME - TRADE</b>	GlucaGen, Glucagon
<b>DRUG CLASSIFICATION</b>	Glucose elevating agent
<b>DOSAGE FORMS</b>	1 mg Solvent with 1 mL solute (kit only), injection
<b>ACTION(S)</b>	- Causes a breakdown of stored glycogen to raise blood glucose levels
<b>INDICATIONS</b>	- Hypoglycemic patient without venous access and inability to administer oral glucose paste (see Glucose, oral)
<b>CONTRAINDICATIONS</b>	- Known or documented hypersensitivity to glucagon
<b>ADULT DOSE / ROUTE</b>	- 1 mg IM/IN
<b>PEDIATRIC DOSE / ROUTE</b>	- ≤ 8 yo = 0.5 mg IM > 8 yo = 1 mg IM
<b>SIDE EFFECTS</b>	- Nausea/vomiting, dizziness, headache



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Glucose Gel
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Glucose Gel</b>
<b>DRUG NAME - TRADE</b>	Glucose 15
<b>DRUG CLASSIFICATION</b>	Glucose elevating agent
<b>DOSAGE FORMS</b>	Net weight of gel 37.5 grams, oral, tube
<b>ACTION(S)</b>	Increases serum glucose level
<b>INDICATIONS</b>	Hypoglycemia in alert patients who are able to follow commands and swallow
<b>CONTRAINDICATIONS</b>	Uncooperative or depressed mental status
<b>ADULT DOSE / ROUTE</b>	One Tube (15 g)
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• 1 mo- 4 years: 1/4 tube</li> <li>• 4- 8 years: 1/2 tube</li> <li>• &gt;8 years: 1 tube</li> </ul>
<b>SIDE EFFECTS</b>	Nausea, potential for aspiration in patients with impaired airway reflexes



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Hydroxocobalamin
Approved: EMS Medical Directors Consortium
Effective: December 6, 2023

<b>DRUG NAME - GENERIC</b>	<b>Hydroxocobalamin</b>
<b>DRUG NAME - TRADE</b>	Cyanokit
<b>DRUG CLASSIFICATION</b>	Antidote for cyanide exposure
<b>DOSAGE FORMS</b>	One kit - 5 gram hydroxocobalamin dark red crystalline powder in a vial to be reconstituted with 200 ml of 0.9% Sodium Chloride
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Contains cobalt compounds that bind to and detoxify cyanide before it inhibits cellular respiration</li> </ul>
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Exposure to products of combustion with smoke inhalation from closed-space fires <u>AND</u></li> <li>• One or more significant cyanide exposure signs or symptoms, such as markedly altered level of consciousness, seizures, respiratory depression or respiratory arrest, cardiac dysrhythmias and hypotension.</li> </ul>
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• Hypersensitivity to hydroxocobalamin, cyanocobalamin or cobalt</li> </ul>
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• IV infusion</li> <li>• Initial dose: 5 grams (one kit) administered over 15 minutes, slow IV</li> <li>• After reconstitution, the vial contains hydroxocobalamin for injection with concentration 25 mg/mL</li> <li>• Considered safe for treatment in pregnant patients</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• IV infusion</li> <li>• 70 mg/kg (reconstitute concentration is 25 mg/mL)</li> <li>• Max dose 5 grams (one kit)</li> </ul>
<b>SIDE EFFECTS</b>	<ul style="list-style-type: none"> <li>• <u>Risk of anaphylaxis or other hypersensitivity reaction</u> - Common reactions include new onset chest tightness, edema, urticaria, pruritis, dyspnea, or rash.</li> <li>• <u>Risk of renal injury</u> – Acute renal failure with acute tubular necrosis, renal impairment, and urine calcium oxalate crystals have been reported after Cyanokit administration.</li> <li>• <u>Risk of substantially increased blood pressure</u> – Monitor blood pressure during treatment.</li> <li>• <u>Red coloring of the urine (chromaturia) and skin (erythema)</u> - This flushing should not be interpreted as an allergic reaction.</li> <li>• <u>Other side effects</u> – headache or infusion site reaction.</li> </ul>
<b>PREPARATION</b>	<ul style="list-style-type: none"> <li>• Visually inspect hydroxocobalamin solutions for particulate matter and color prior to administration. If the reconstituted solution is not dark red or if particulate matter is observed after the solution has been appropriately mixed, the solution should be discarded.</li> <li>• Any reconstituted product not used within 6 hours should be discarded.</li> <li>• Use a separate IV line for administration of hydroxocobalamin.</li> </ul>






**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Hydroxocobalamin

Approved: EMS Medical Directors Consortium

Effective: December 6, 2023

- **Reconstitute:** Place the vial in an upright position. Add 200 ml of 0.9% Sodium Chloride Injection to the vial using the transfer spike. Fill to the line.
- **Mix:** The vial should be repetitively inverted or rocked, not shaken, for at least 60 seconds prior to infusion. Visually inspect the solution for particulate matter and color prior to administration. Discard solution if particulate matter is present or solution is not dark red.
- **Infuse vial:** Using vented intravenous tubing, hang and infuse over 15 minutes.





**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Ipratropium
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Ipratropium</b>
<b>DRUG NAME - TRADE</b>	Atrovent
<b>DRUG CLASSIFICATION</b>	Bronchodilator, Anticholinergic
<b>DOSAGE FORMS</b>	0.02%, 0.5 mg/2.5 mL, inhalation, vial
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Anticholinergic agent</li> <li>• Results in bronchial smooth muscle relaxation and bronchodilation</li> </ul>
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Asthma</li> <li>• Bronchitis with bronchospasm</li> <li>• COPD with wheezing</li> </ul>
<b>CONTRAINDICATIONS</b>	Known or documented hypersensitivity
<b>ADULT &amp; PEDIATRIC DOSE / ROUTE</b>	0.5 mg (2.5 mL) via nebulizer (6 LPM oxygen) mixed with albuterol until mist stops, usually 5-15 minutes
<b>SIDE EFFECTS</b>	Common side effects include palpitations, tachydysrhythmia, anxiety, tremors, nausea/vomiting Rarely, paradoxical bronchospasm can occur



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Midazolam
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Midazolam</b>
<b>DRUG NAME - TRADE</b>	Versed
<b>DRUG CLASSIFICATION</b>	Benzodiazepine, sedative-hypnotic, anticonvulsant
<b>DOSAGE FORMS</b>	10 mg/2 mL, injection, vial
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Suppresses seizures, causes sedation and muscle relaxation</li> <li>• Enhances effects of GABA neurotransmitter</li> </ul>
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Active seizure</li> <li>• Behavioral emergency not responsive to verbal de-escalation</li> </ul>
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• Known or documented allergy/hypersensitivity</li> <li>• Acute narrow angle glaucoma</li> <li>• Severe respiratory depression (except during mechanical ventilation)</li> <li>• Caution in COPD, renal failure, CHF, elderly, pregnancy, concomitant alcohol or CNS depressant medication use</li> </ul>
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Seizure: 2 - 5mg IV/IO, may repeat X1 after 5 minutes if seizures persist (10mg max) <b>OR</b> 10 mg IN or 5mg IM</li> <li>• Behavioral Emergency: 2mg IV, may repeat X1 after 5 minutes <b>OR</b> 5mg IN/IM (Age &gt; 60 contact OLMC for approval)</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Seizures 0.1 mg/kg slow IV/IO/IM or 0.2 mg/kg IN. If seizures continue &gt; 5 minutes, may repeat X1.</li> <li>• Maximum total dose: &lt; 6 years = 6 mg ≥ 6 years = 10 mg</li> </ul>
<b>SIDE EFFECTS</b>	Excessive CNS depression, apnea, amnesia, confusion, ataxia, hypotension, euphoria, and rarely paradoxical reactions (aggressiveness, restlessness)



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Naloxone
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Naloxone</b>
<b>DRUG NAME - TRADE</b>	Narcan
<b>DRUG CLASSIFICATION</b>	Opioid antagonist
<b>DOSAGE FORMS</b>	2 mg/2 ml, injection, Prefilled Syringe
<b>ACTION(S)</b>	Binds the opioid receptor and blocks the effects of opioids
<b>INDICATIONS</b>	Reversal of acute respiratory depression from suspected opioid toxicity
<b>CONTRAINDICATIONS</b>	None
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• ALS 1-2 mg IV/IO/IM or 2mg nebulized OR IN</li> <li>• BLS 2 mg IN</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• ALS ≤ 20 kg: 0.1 mg/kg IV/IO/IM/IN up to 2 mg. &gt;20 kg: 2 mg IV/IO/IM/IN</li> <li>• BLS 0-4 years old: 1 mg IN &gt;4 years old 2 mg IN</li> </ul>
<b>SIDE EFFECTS</b>	Withdrawal symptoms (agitation, nausea, vomiting), tachycardia, hypertension, seizures.



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Nitroglycerin
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Nitroglycerin</b>
<b>DRUG NAME - TRADE</b>	Nitrostat
<b>DRUG CLASSIFICATION</b>	Vasodilator
<b>DOSAGE FORMS</b>	0.4 mg sublingual tablet, bottle
<b>ACTION(S)</b>	Smooth muscle relaxant resulting in peripheral vasodilation
<b>INDICATIONS</b>	Ischemic chest pain (angina, AMI), pulmonary edema
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• SBP &lt; 100 mm Hg</li> <li>• Known or documented hypersensitivity</li> <li>• Recent use of erectile dysfunction medications (sildenafil (Viagra® – within last 24 hours), tadalafil (Cialis® – within last 48 hours), vardenafil (Levitra® – within last 48 hours), or other phosphodiesterase-5 inhibitors</li> <li>• Pulmonary hypertension medications (Revatio, Adempas, sildenafil, riociguat) may increase the effects of nitrates</li> <li>• Caution in patients with concern for inferior wall/right ventricular myocardial infarction</li> </ul>
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• <b>BLS Cardiac Chest Pain:</b> Assist patient with 0.4 mg sublingual tablet. May repeat q 3-5 minutes for continued chest pain if systolic BP ≥ 100. (Max 3 doses)</li> <li>• <b>ALS Suspected ACS/Pulmonary Edema:</b> 0.4 mg sublingual tablet. May repeat q 3-5 minutes for continued CP if systolic BP ≥ 100. (Max 3 doses)</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	N/A
<b>SIDE EFFECTS</b>	Headache, hypotension, nausea/vomiting, flushing, orthostatic hypotension/syncope



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Ondansetron
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Ondansetron</b>
<b>DRUG NAME - TRADE</b>	Zofran
<b>DRUG CLASSIFICATION</b>	Antiemetic
<b>DOSAGE FORMS</b>	4 mg/2 mL, injection, vial OR 4 mg oral disintegrating tablet (ODT)
<b>ACTION(S)</b>	Selective serotonin 5- HT3 receptor antagonist
<b>INDICATIONS</b>	Nausea, vomiting
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• Known or documented hypersensitivity</li> <li>• Congenital heart surgery or congenital heart disease</li> <li>• Severe hepatic impairment</li> <li>• Known or suspected prolonged QT interval</li> </ul>
<b>ADULT DOSE / ROUTE</b>	4 mg IV or 4 mg ODT (place on top of tongue and allow to dissolve, then swallow with saliva)
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• &gt; 1 year old and 10 kg: consider 0.15 mg/kg slow IV max dose 4mg</li> <li>• &gt; 25 kg: 4 mg oral disintegrating tablet (ODT). No oral dose for &lt; 25 kg</li> </ul>
<b>SIDE EFFECTS</b>	<ul style="list-style-type: none"> <li>• Diarrhea, headache, lightheadedness.</li> <li>• May prolong QT interval</li> </ul>



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Oxygen
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Oxygen</b>
<b>DRUG NAME - TRADE</b>	N/A
<b>DRUG CLASSIFICATION</b>	Medical gas
<b>ACTION(S)</b>	Raises the amount of oxygen in the blood and, therefore, the amount delivered to the tissues
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Hypoxemia</li> <li>• Respiratory distress</li> <li>• Shock (decreased oxygenation of tissues) from any cause</li> <li>• Smoke inhalation</li> <li>• Carbon monoxide poisoning</li> <li>• Cardiac Arrest</li> </ul>
<b>CONTRAINDICATIONS</b>	None
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Administer oxygen to maintain an oxygen saturation of &gt;94%. 1 L to 15 L per minute (nasal cannula or non-rebreather mask as needed)</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• For any critically ill patient (respiratory distress, shock, smoke inhalation, carbon monoxide poisoning or cardiac arrest) 15 L per minute non-rebreather mask</li> </ul>
<b>SIDE EFFECTS</b>	<ul style="list-style-type: none"> <li>• Drying and irritating to mucous membranes</li> <li>• Mild Euphoria</li> </ul>



**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Pralidoxime
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Pralidoxime</b>
<b>DRUG NAME - TRADE</b>	2-PAM
<b>DRUG CLASSIFICATION</b>	Oxime, antidote for organophosphate and nerve agent poisoning
<b>DOSAGE FORMS</b>	<ul style="list-style-type: none"> <li>• Duodote: 600 mg IM</li> <li>• Mark 1 Kit: 600 mg IM</li> <li>• 20 ml vial containing 1 gram powder (50 mg/ml) (must be reconstituted with sterile water).</li> </ul>
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Binds to organophosphates and breaks alkyl phosphate-cholinesterase bond to restore activity of acetylcholinesterase</li> </ul>
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• For the management of toxicity caused by organophosphate insecticides and nerve agent poisoning (e.g. tabun, sarin, soman) including muscle fasciculations, nausea and vomiting, copious secretions, bradycardia, weakness, shortness of breath, unconsciousness, convulsions, paralysis and apnea.</li> <li>• MUST be used in conjunction with atropine</li> </ul>
<b>CONTRAINDICATIONS</b>	Documented hypersensitivity
<b>ADULT DOSE / ROUTE</b>	600 mg IM, may repeat x 2 for total of 1800 mg
<b>PEDIATRIC DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Pediatric nerve agent/organophosphate exposure dosages are not included in the Drug Appendix.</li> <li>• See Protocol: HAZ MAT / NERVE AGENTS - PEDIATRIC - ALS</li> </ul>
<b>SIDE EFFECTS</b>	Hypertension, tachycardia, dizziness, blurred vision





**REGION 11  
CHICAGO EMS SYSTEM  
DRUG TABLE**

Drug Name: Sodium Bicarbonate 8.4%
Approved: EMS Medical Directors Consortium
Effective: August 1, 2022

<b>DRUG NAME - GENERIC</b>	<b>Sodium Bicarbonate 8.4%</b>
<b>DRUG NAME - TRADE</b>	N/A
<b>DRUG CLASSIFICATION</b>	Electrolyte replacement, Alkalinizing Agent
<b>Dosage Forms</b>	50 mEq/50 ml, injection, prefilled syringe
<b>ACTION(S)</b>	<ul style="list-style-type: none"> <li>• Buffers acidosis in chronic renal failure/dialysis patients who are unstable or in cardiac arrest</li> <li>• Shifts potassium into cells</li> <li>• Slows uptake of cyclic antidepressants.</li> </ul>
<b>INDICATIONS</b>	<ul style="list-style-type: none"> <li>• Cardiac arrest or wide complex tachycardia with pulse AND suspected hyperkalemia</li> <li>• Consider with wide complex tachycardia or cardiac arrest secondary to suspected tricyclic antidepressant overdose.</li> <li>• Adult crush injuries with victim still entrapped</li> </ul>
<b>CONTRAINDICATIONS</b>	None for indications as listed
<b>ADULT DOSE / ROUTE</b>	<ul style="list-style-type: none"> <li>• Adults - Cardiac Arrest/Wide Complex Tachycardia: Sodium Bicarbonate 8.4% 50 mEq/50 mL injection of prefilled syringe IV/IO</li> <li>• Adults - Crush injury with victim still entrapped: Sodium bicarbonate 8.4% 1 mEq/kg (maximum dose of 50 mEq) IV/IO</li> </ul>
<b>PEDIATRIC DOSE / ROUTE</b>	Call OLMC
<b>SIDE EFFECTS</b>	Minimal when used as indicated.